Education
About Us
Working with TipRanks
Follow Us
CareDx (CDNA)
NASDAQ:CDNA
CDNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.90 - $34.84
Previous CloseN/A
Volume177.07K
Average Volume (3M)989.42K
Market Cap
$910.93M
Enterprise ValueN/A
Total Cash (Recent Filing)$230.92M
Total Debt (Recent Filing)$30.28M
Price to Earnings (P/E)14.2
Beta1.72
Next Earnings
Aug 12, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding55,680,550
10 Day Avg. Volume1,654,879
30 Day Avg. Volume989,418
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)2.21
Price to Sales (P/S)0.00
P/FCF Ratio33.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$28.00Price Target Upside73.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
CareDx News
PremiumCompany Announcements
CareDx Inc. Reports Strong Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Cash PositionThe company had $230.9M in cash and investments, indicating a strong cash position.
Revenue GrowthTotal revenue was $84.7M, representing 17.5% YoY growth and beating our projection of $84.0M.
Bears Say
Net LossNet loss was between $32-34M for 4Q24 and between $58-60M for FY2024.
Stock PerformanceShares of CDNA are off 9% after the company delivered an in-line Q1 and reiterated its full-year guidance, which we view as a significant overreaction for an in-line quarter.
---
Ownership Overview
9.52% Insiders
25.59% Mutual Funds
0.07% Other Institutional Investors
42.78% Public Companies and
Individual Investors
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $12.90 and its highest was $34.84 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is $910.93M.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Aug 12, 2025 which is in 90 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Apr 30, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.207 by $0.017.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is -0.1.
How many shares outstanding does CareDx have?
CareDx has 55,680,550 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.207. Following the earnings report the stock price went down -10.723%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in CDNA
---
CareDx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.00 (73.59% Upside)
$28.00 (73.59% Upside)
Blogger Sentiment
Neutral
CDNA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 759.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $623.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.31%
12-Months-Change
Fundamentals
Return on Equity
21.57%
Trailing 12-Months
Asset Growth
8.23%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
---
CDNA Company Deck
---
CDNA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong revenue growth, successful product expansions, and operational improvements. However, the impact of weather on testing volumes and the financial implications of the securities settlement present challenges.Read More>---
CDNA Stock 12 Month Forecast
Average Price Target
$28.00
▲(73.59% Upside)
Technical Analysis
---